Evidence map›Paper›PMID 40872337›Full record

ArticlePathogens (Basel, Switzerland)2025

Anti-SARS-CoV-2 Antibodies in Urine of Individuals Vaccinated with Janssen AD26.COV2.S COVID-19 Vaccine.

Marina F N Melo, Rômulo C D Lira, Raquel S B Câmara, Isabela A G Pereira, Fernanda F Ramos, Carolina S F Costa, Laura F Amorim, Quezia D Teixeira, Flávio G da Fonseca, Vandack Nobre and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Marina F N MeloPrograma de Pós-Graduação em Ciências da Saúde, Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 30.130-100, Minas Gerais, Brazil.
Rômulo C D LiraPrograma de Pós-Graduação em Ciências da Saúde, Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 30.130-100, Minas Gerais, Brazil.ORCID 0000-0003-1375-4082
Raquel S B CâmaraPrograma de Pós-Graduação em Ciências da Saúde, Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 30.130-100, Minas Gerais, Brazil.
Isabela A G PereiraPrograma de Pós-Graduação em Ciências da Saúde, Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 30.130-100, Minas Gerais, Brazil.
Fernanda F RamosPrograma de Pós-Graduação em Ciências da Saúde, Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 30.130-100, Minas Gerais, Brazil.ORCID 0000-0002-7852-0300
Carolina S F CostaPrograma de Pós-Graduação em Ciências da Saúde, Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 30.130-100, Minas Gerais, Brazil.
Laura F AmorimPrograma de Pós-Graduação em Ciências da Saúde, Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 30.130-100, Minas Gerais, Brazil.
Quezia D TeixeiraPrograma de Pós-Graduação em Ciências da Saúde, Faculdade de Ciências Médicas de Minas Gerais, Belo Horizonte 30.130-110, Minas Gerais, Brazil.
Flávio G da FonsecaLaboratório de Virologia Básica e Aplicada, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte 31.270-901, Minas Gerais, Brazil.ORCID 0000-0002-1416-8694
Vandack NobrePrograma de Pós-Graduação em Ciências da Saúde, Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 30.130-100, Minas Gerais, Brazil.ORCID 0000-0002-7922-0422
Flavia G F FerreiraDepartamento de Pediatria, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 30.130-100, Minas Gerais, Brazil.ORCID 0009-0003-3430-255X
Jorge PintoDepartamento de Pediatria, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 30.130-100, Minas Gerais, Brazil.ORCID 0000-0003-2987-3238
Eduardo A F CoelhoPrograma de Pós-Graduação em Ciências da Saúde, Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 30.130-100, Minas Gerais, Brazil.ORCID 0000-0002-6681-9014
Fernanda LudolfPrograma de Pós-Graduação em Ciências da Saúde, Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 30.130-100, Minas Gerais, Brazil.ORCID 0000-0003-3357-9816
Júlia F M CaporaliPrograma de Pós-Graduação em Ciências da Saúde, Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 30.130-100, Minas Gerais, Brazil.

Funding

Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-02167-21 and RED-0067-23National Council for Scientific and Technological Development 402417/2023-2 and BP - 100/2024
6 · The paper itself

Abstract

Urine-based immunoassay is a non-invasive method with demonstrated utility in detecting anti-SARS-CoV-2 antibodies in unvaccinated patients with COVID-19. To evaluate urine's potential for serological surveys in a real-world setting, SARS-CoV-2 serology was performed on urine samples from vaccinated individuals, both with and without prior confirmed COVID-19. (1) Methods: An in-house indirect ELISA was used to measure antibodies against recombinant spike (S) and nucleocapsid (N) proteins of SARS-CoV-2 in urine and paired serum from 149 individuals vaccinated with Janssen AD26.COV2.S, an S protein-based COVID-19 vaccine. (2) Results: Anti-S and anti-N levels were higher in the urine and serum of participants with confirmed prior COVID-19 compared to those without prior infection. Urinary anti-S effectively distinguished vaccinated individuals with (AUC = 0.96) and without (AUC = 0.88) prior infection from negative controls (non-vaccinated, non-previously infected individuals) (

Indexed as

Antibodies, ViralCOVID-19COVID-19 VaccinesSARS-CoV-2Ad26COVS1AdultAgedCoronavirus Nucleocapsid ProteinsCOVID-19 Serological TestingEnzyme-Linked Immunosorbent AssayFemaleHumansMaleMiddle AgedPhosphoproteinsSpike Glycoprotein, CoronavirusAd26COVS1Antibodies, ViralCoronavirus Nucleocapsid ProteinsCOVID-19 Vaccinesnucleocapsid phosphoprotein, SARS-CoV-2PhosphoproteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2AD26.COV2.SCOVID-19ELISAimmunoassaySARS-CoV-2urine

Identifiers

PMID40872337
PMCPMC12389031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.